Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Gilead’s Lucrative Hep C Patents Face PTAB Assault
Gilead faces challenge to U.S. hepatitis C patents from advocacy group
Consumer group challenges Gilead patents on hepatitis C drug
Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty
First-Ever U.S. Patent Challenges Dispute Gilead’s Monopoly on Hepatitis C Drugs that Blocks Millions from Treatment
Under-the-radar SCOTUS patent case could have big implications for drug prices, access
Patents, Licenses and Drug Prices
Supreme Court Case Could Threaten America’s Ability to Lower Exorbitant Drug Prices, New Policy Brief Warns
DEEP DIVE OPINION: Increasing access to medicines: A critical look at pharmaceutical patents